Current world literature. Myeloid biology.

Bibliography Current World Literature This bibliography is compiled by clinicians from the journals listed at the end of this publication. It is based on literature entered into our database between 1 September 2009 and 31 August 2010 (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.

Papers considered by the reviewers to be of special interest Papers considered by the reviewers to be of outstanding interest The number in square brackets following a selected paper, e.g. [7], refers to its number in the annotated references of the corresponding review. Current Opinion in Hematology 2011, 18:63–70 # 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins 1065-6251

Myeloid biology A comparison of international guidelines for the prevention of chemotherapyinduced neutropenia Review: (pp. 1–10) Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? [Review]. Support Care Cancer 2010; 18:529– 541. Abuali MM, Posada R, Del Toro G, Roman E, et al. Rhizomucor variabilis var. regularior and Hormographiella aspergillata Infections in a Leukemic Bone Marrow Transplant Recipient with Refractory Neutropenia. J Clin Microbiol 2009; 47:4176–4179. Al-Badriyeh D, Slavin M, Liew D, Thursky K, et al. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. J Antimicrob Chemother 2010; 65:1052– 1061. Bakhshi S, Singh P, Swaroop C. Outpatient consolidation chemotherapy in pediatric acute myeloid leukemia: a retrospective analysis. Hematology 2009; 14:255–260. Beaupain B, Leblanc T, Reman O, Hermine O, et al. Is Pegfilgrastim Safe and Effective in Congenital Neutropenia? An Analysis of the French Severe Chronic Neutropenia Registry. Pediatric Blood Cancer 2009; 53:1068–1073. Brugger W, Bacon P, Lawrinson S, Romieu G. Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support [Review]. Crit Rev Oncol/Hematol 2009; 72:265–269. Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer 2009; 101:S18–S22. Carnino L, Betteto S, Loiacono M, Chiappella A, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol 2010; 136:611–615.

Contents Myeloid biology 63 A comparison of international guidelines for the prevention of chemotherapyinduced neutropenia 64 Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease 65 Neutrophil serine proteases: mediators of innate immune responses 65 Pathophysiological importance of antineutrophil antibodies in vasculitis 65 Physiological role of IL-8 and its receptors 65 Clinical spectrum and molecular pathophysiology of Shwachman– Diamond syndrome 65 Advances in the diagnosis and treatment of chronic granulomatous disease

Vol 18 No 1 January 2011

66 Infectious mononucleosis and return to play 66 Neutropenia and other hematological complications of tyrosine kinase inhibitor therapy 67 Myelopoiesis 67 Pattern recognition receptors 67 Neutropenia 67 Transcriptional regulation of myeloid cells 67 Advances in therapeutics 68 Biomarkers, diagnostic and prognostic indicators 68 Congenital myeloid diseases 69 Myeloid leukaemia 69 Inflammation and infection 70 Miscellaneous

65 Clinical spectrum, pathophysiology and treatment of the Wiskott– Aldrich syndrome 66 Neutropenia associated with rituximab therapy 66 Advances in diagnosis and treatment of large granular lymphocyte syndrome

Chen ML, Fang CH, Sen Liang L, Dai LH, et al. A meta-analysis of chemotherapy regimen Fluorouracil/Leucovorin/ Oxaliplatin Compared with Fluorouracil/Leucovorin in treating advanced colorectal cancer [Review]. Surg Oncol-Oxf 2010; 19:38–45. Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw 2009; 7:64–83. [29] Crea F, Giovannetti E, Zinzani PL, Danesi R. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization [Review]. Crit Rev Oncol/Hematol 2009; 72:21–44. Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer 2009; 101:S11– S14. Cuomo G, Abignano G, Valentini G. Early onset neutropenia after mycophenolate mofetil in systemic sclerosis. Rheumatol Int 2009; 29:1529–1530. Czuchlewski DR, Brackney M, Ewers C, Manna J, et al. Clinicopathologic Features of Agranulocytosis in the Setting of Levamisole-Tainted Cocaine. Am J Clin Pathol 2010; 133:466–472. Dufour C, Cappelli B, Calvillo M, Fioredda F, et al. Similar favorable outcome of pegfilgrastim overdose in patients with different age and underlying disease. Haematologica 2010; 95:684–685. Engert A, del Giglio A, Bias P, Lubenau H, et al. Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma. Onkologie 2009; 32:599–604. Fox E, Widemann BC, Hawkins DS, Jayaprakash N, et al. Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas. Clin Cancer Res 2009; 15:7361–7367. Fridrik MA, Hausmaninger H, Lang A, et al. Dose-dense therapy improves survival in aggressive non-Hodgkin’s lymphoma. Ann Hematol 2010; 89:273–282. [38] Fujita H, Yoshida M, Miura K, Sano T, et al. Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group. Int J Hematol 2009; 90:191–198.

Gagliano A, Masi G. Clozapine-Aripiprazole Association in a 7-Year-Old Girl with Schizophrenia: Clinical Efficacy and Successful Management of Neutropenia with Lithium. J Child Adolesc Psychopharmacol 2009; 19:595–598. Garzotto M, Higano CS, O’Brien C, Rademacher BLS, et al. Phase 1/2 Study of Preoperative Docetaxel and Mitoxantrone for High-Risk Prostate Cancer. Cancer 2010; 116:1699–1708. Gayol MD, Font A, Casas I, Estrada O, et al. Usefulness of the MASCC scale in the management of neutropenic fever induced by chemotherapy in patients with solid neoplasm [Spanish]. Med Clin (Barc) 2009; 133:296–299. Hahn-Ast C, Glasmacher A, Muckter S, Schmitz A, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010; 65:761–768. Hansson EK, Wallin JE, Lindman H, Sandstrom M, et al. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 2010; 65:839–848. Heaney ML, Toy EL, Vekeman F, Laliberte F, et al. Comparison of Hospitalization Risk and Associated Costs Among Patients Receiving Sargramostim, Filgrastim, and Pegfilgrastim for Chemotherapy-Induced Neutropenia. Cancer 2009; 115:4839–4848. Hecht JR, Pillai M, Gollard R, Heim W, et al. A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy. Clin Colorectal Canc 2010; 9:95–101. Hung YP, Lee NY, Chang CM, Lee HC, et al. Tolerability of Teicoplanin in 117 Hospitalized Adults With Previous Vancomycin-Induced Fever, Rash, or Neutropenia: A Retrospective Chart Review. Clin Ther 2009; 31:1977–1986. Hwang YY, Liang R. Antifungal prophylaxis and treatment in patients with hematological malignancies [Review]. Expert Rev Anti-Infect Ther 2010; 8:397–404. Ishiguro H, Kondo M, Hoshi SL, Takada M, et al. Economic Evaluation of Intensive Chemotherapy With Prophylactic Granulocyte Colony-Stimulating Factor for Patients With High-Risk Early Breast Cancer in Japan. Clin Ther 2010; 32:311–326.

63

Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.

64 Myeloid biology Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease Jones AL, Leonard R. Breast cancer: Improved care through effective management of febrile neutropenia - Foreword. Br J Cancer 2009; 101:S1. Kishida Y, Kawahara M, Teramukai S, Kubota K, et al. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. Br J Cancer 2009; 101:1537–1542. Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer 2009; 101:S23–S26. Lathia N, Mittmann N, De Angelis C, Knowles S, et al. Evaluation of Direct Medical Costs of Hospitalization for Febrile Neutropenia. Cancer 2010; 116:742–748. Lech-Maranda E, Seweryn M, Giebel S, Holowiecki J, et al. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). Int J Infect Dis 2010; 14:E132– E140. Leong SS, Fong KW, Lim WT, Toh CK, et al. A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer 2010; 67:325–329. Lipton A, Campbell-Baird C, Witters L, Harvey H, et al. Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer. J Clin Gastroenterol 2010; 44:286–288. Lodato F, Azzaroli F, Tame MR, Di Girolamo M, et al. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. World J Gastroenterol 2009; 15:5449–5454. Lunel FMV, Mennink-Kersten MASH, Ruegebrink D, van der Lee HAL, et al. Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagn Microbiol Infect Dis 2009; 64:408– 415. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009; 7:99– 108. [11] Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28:2914– 2924. [37] Ma BBY, Hui EP, Mok TSK. Population-based differences in treatment outcome following anticancer drug therapies [Review]. Lancet Oncol 2010; 11:75–84. Maione P, Rossi A, Di Maio M, Gridelli C. Tumor-related leucocytosis and chemotherapy-induced neutropenia: Linked or independent prognostic factors for advanced non-small cell lung cancer? [Review]. Lung Cancer 2009; 66:8–14. Mattai A, Fung L, Bakalar J, Overman G, et al. Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children. Hum Psychopharmacol-Clin Exp 2009; 24:584–589. Milano-Bausset E, Gaudart J, Rome A, Coze C, et al. Retrospective Comparison of Neutropenia in Children With Ewing Sarcoma Treated With Chemotherapy and Granulocyte Colony-Stimulating Factor (G-CSF) or Pegylated G-CSF. Clin Ther 2009; 31:2388–2395. Montella L, Addeo R, Guarrasi R, Cennamo G, et al. Once-percycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide. Eur J Cancer Care 2010; 19:200–204. Poele EMT, Tissing WJE, Kamps WA, de Bont ESJM. Risk assessment in fever and neutropenia in children with cancer: What did we learn? [Review]. Crit Rev Oncol/ Hematol 2009; 72:45–55. Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2009; 12:217– 225. [42] Renwick W, Pettengell R, Green M. Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy Twenty Years of Clinical Experience [Review]. Biodrugs 2009; 23:175–186. Repetto L. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey [Review]. Crit Rev Oncol/Hematol 2009; 72:170–179. Rettenbacher MA, Hofer A, Kemmler G, Fleischhacker WW. Neutropenia Induced by Second Generation Antipsychotics: A Prospective Investigation. Pharmacopsychiatry 2010; 43:41–44.

Scholz M, Ackermann M, Engel C, Emmrich F, et al. A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia. Cell Prolif 2009; 42:813–822. Shayne M, Culakova E, Wolff D, et al. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer 2009; 115:5319–5328. [14] Slobbe L, van der Waal L, Jongman LR, Lugtenburg PJ, et al. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: A prospective observational safety study. Eur J Cancer 2009; 45:2810–2817. Smith JA, Kauffman CA. Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-alpha Inhibitor Therapy. Drugs 2009; 69:1403–1415. Tewari S, Sharma RK, Abrol P, Sen R. Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108:E13–E19. Thirumala R, Ramaswamy M, Chawla S. Diagnosis and Management of Infectious Complications in Critically Ill Patients with Cancer [Review]. Crit Care Clin 2010; 26:59–. Torres A, Serrano J, Rojas R, Martin V, et al. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol 2010; 84:271–273. Trueman P. Prophylactic G-CSF in patients with early-stage breast cancer : a health economic review. Br J Cancer 2009; 101:S15–S17. Uygun V, Karasu GT, Ogunc D, Yesilipek A, et al. Piperacillin/Tazobactam Versus Cefepime for the Empirical Treatment of Pediatric Cancer Patients With Neutropenia and Fever: A Randomized and Open-Label Study. Pediatric Blood Cancer 2009; 53:610–614. Verrill M. Chemotherapy for early-stage breast cancer: a brief history. Br J Cancer 2009; 101:S2–S5. von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis. Eur J Cancer 2009; 45:608–617. [39] Wingard JR, Elmongy M. Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics [Review]. Crit Rev Oncol/ Hematol 2009; 72:144–154. Yano Y, Kodawara T, Hongo H, Yano I, et al. Population Analysis of Myelosuppression Profiles Using Routine Clinical Data after the ICE (Ifosfamide/Carboplatin/ Etoposide) Regimen for Malignant Gliomas. J Pharm Sci 2009; 98:4402–4412.

Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease Review: (pp. 11–18) Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, et al. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med 2010; 36:452–461. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology [Review]. Eur J Clin Invest 2010; 40:273–276. Che M, Xie B, Xue S, et al. Clinical usefulness of novel biomarkers for the detection of acute kidney injury following elective cardiac surgery. Nephron Clin Pract 2010; 115:c66–c72. [71] Constantin JM, Futier E, Perbet S, et al. Plasma neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in adult critically ill patients: a prospective study. J Crit Care 2010; 25:176– 1176. [63] Cruz DN, de Cal M, Garzotto F, et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010; 36:444–451. [60] Cruz DN, de Cal M, Garzotto F, Perazella MA, et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010; 36:444–451.

Devireddy LR, Hart DO, Goetz DH, Green MR. A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell 2010; 141:1006–1017. [25] Gandorfer A, Thurau S. Acute retinal necrosis [German]. Ophthalmologe 2009; 106:751–759. Gaspari F, Cravedi P, Mandala` M, et al. Predicting cisplatin induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract 2010; 115:c154–c160. [33] Goldstein SL, Chawla LS. Renal angina. Clin J Am Soc Nephrol 2010; 5:943–949. [87] Haase-Fielitz A, Bellomo R, Devarajan P, et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery: a prospective cohort study. Crit Care Med 2009; 37:553– 560. [70] Haase-Fielitz A, Bellomo R, Devarajan P, et al. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol Dial Transplant 2009; 24:3349–3354. [81] Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury (AKI): a systematic review and meta-analysis. Am J Kidney Dis 2009; 54:1012– 1024. [80] Haase M, Haase-Fielitz A, Bellomo R, et al. Sodium bicarbonate to prevent acute kidney injury after cardiopulmonary bypass: a multiple-blind, randomized controlled trial. Crit Care Med 2009; 37:39–47. [08] Hall IE, Yarlagadda SG, Coca SG, et al. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 2010; 21:189–197. [76] Hille A, Rave-Frank M, Christiansen H, Herrmann MKA, et al. Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: Results of a prospective study. Scand J Gastroenterol 2009; 44:939–946. Hinze CH, Suzuki M, Klein-Gitelman M, et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 2009; 60:2772–2781. [39] Hollmen M, Kyllo¨nen L, Inkinen K, et al. Urine neutrophil gelatinase-associated lipocalin: a marker for graft recovery after kidney transplantation. Kidney Int (in press). [79] Little K, Noland B, Kupfer K, et al. Measurement of admission neutrophil gelatinase-associated lipocalin value for risk assessment of severe acute kidney injury in an adult heterogeneous ICU population. NDT Plus 2(Suppl 2)2009:ii842. doi: 10.1093/ndtplus/2.s2.4 [59] Makris K, Markou N, Evodia E, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 2009; 47:79–82. [57] Malyszko J, Malyszko JS, Mysliwiec M. Serum neutrophil gelatinase-associated lipocalin correlates with kidney function in renal allograft recipients. Clin Transplant 2009; 23:681–686. Martensson J, Bell M, Oldner A, et al. Neutrophil gelatinase associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 2010; 36:1333–1340. [62] Niemann CU, Walia A, Waldman J, Davio M, et al. Acute Kidney Injury During Liver Transplantation as Determined by Neutrophil Gelatinase-Associated Lipocalin. Liver Transplant 2009; 15:1852–1860. Prabhu A, Sujatha DI, Ninan B, Vijayalakshmi MA. Neutrophil gelatinase associated lipocalin as a biomarker for acute kidney injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Ann Vasc Surg 2010; 24:525–531. [72] Shapiro NI, Trzeciak S, Hollander JE, et al. The diagnostic accuracy of plasma neutrophil gelatinase-associated lipocalin in the prediction of acute kidney injury in emergency department patients with suspected sepsis. Ann Emerg Med 2010; 56:52–59. [61] Siew ED, Ware LB, Gebretsadik T, Shintani A, et al. Urine Neutrophil Gelatinase-Associated Lipocalin Moderately Predicts Acute Kidney Injury in Critically III Adults. J Am Soc Nephrol 2009; 20:1823–1832. Tuladhar SM, Pu¨ntmann VO, Soni M, et al. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharmacol 2009; 53:261–266. [69]


Myeloid biology Clinical spectrum, pathophysiology and treatment of the Wiskott–Aldrich syndrome 65 Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, MichalukSkutnik J. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol 2010; 25:889–897. Yilmaz A, Sevketoglu E, Gedikbasi A, Karyagar S, et al. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatr Nephrol 2009; 24:2387–2392.

Neutrophil serine proteases: mediators of innate immune responses Review: (pp. 19–24) Guma M, Ronacher L, Liu-Bryan R, et al. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 2009; 60:3642–3650. [24] Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010; 107:9813–9818. [11] Houghton AM, Rzymkiewicz DM, Ji H, et al. Neutrophil elastase mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 2010; 16:219–223. [46] Jackson PL, Xu X, Wilson L, et al. Human neutrophil elastase mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. Mol Med 2010; 16:159–166. [40] Joosten LA, Netea MG, Fantuzzi G, et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 2009; 60:3651–3662. [25] Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15:623–625. [13] Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16:887– 896. [15] McGreal EP, Davies PL, Powell W, et al. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochim Biophys Acta 2010; 1802:649–658. [41] Tejera P, Wang Z, Zhai R, et al. Genetic polymorphisms of peptidase inhibitor 3 (elafin) are associated with acute respiratory distress syndrome. Am J Respir Cell Mol Biol 2009; 41:696–704. [43]

Pathophysiological importance of antineutrophil antibodies in vasculitis Review: (pp. 25–29) Chen M, Kallenberg CGM. New advances in the pathogenesis of ANCA-associated vasculitides [Review]. Clin Exp Rheumatol 2009; 37:S108–S114. Chipczynska B, Gralek M, Hautz W, Zegadlo-Mylik M, et al. Orbital tumor as an initial manifestation of Wegener’s granulomatosis in children: A series of four cases. Med Sci Monitor 2009; 15:CS135–CS138. Erwig LP, Savage CO. ANCA-associated vasculitides: advances in pathophysiology and treatment. Neth J Med 2010; 68:62–67. [03] Fournier A, Nony A, Rifard K. Antineutrophil cytoplasmic antibody associated vasculitis in a patient treated with adalimumab for a rheumatoid arthritis [French]. Nephrol Ther 2009; 5:652–657. Holl-Ulrich K. Histopathology of systemic vasculitis [Review] [German]. Pathologe 2010; 31:67–75. Ishii K, Kadota E, Shimizu M, Nomura S. Fatal TRALI Associated with Neutrophil Antibodies in a Recipient of Pre-Storage Leukocyte-Reduced Blood Components. Intern Med 2009; 48:1429–1431. Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15:623–625. [28] Little MA, Smyth L, Salama AD, et al. Experimental autoimmune vasculitis: an animal model of antineutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol 2009; 174:1212–1220. [17] McKinney EF, Lyons PA, Carr EJ, et al. A CD8þ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010; 16:586–591. [23] Montagnac R, Nyandwi J, Loiselet G, Pradel J, et al. Ophthalmic manifestations in Wegener’s granulomatosis. Review of literature about an observation [Review] [French]. Nephrol Ther 2009; 5:603–613.

Montiel JL, Monsivais-Urenda A, Figueroa-Vega N, Moctezuma JF, et al. Anti-CD43 and anti-galectin-1 autoantibodies in patients with systemic lupus erythematosus. Scand J Rheumatol 2010; 39:50–57. Morgan MD, Day CJ, Piper KP, Khan N, et al. Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 2010; 130:64–73. Nogueira E, Hamour S, Sawant D, et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2010; 25:2209–2217. [24] Primo VC, Marusic S, Franklin CC, et al. Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis. Clin Exp Immunol 2010; 159:327–337. [18] Qu SB, Khan S, Liu H. Primary central nervous system vasculitis mimicking brain tumour: case report and literature review [Review]. Rheumatol Int 2009; 30:127–134. Riera NE, Salto MR, Galan V, Canalejo K, et al. Antipolymorphonuclear neutrophil antibodies in patients with leukopenia or neutropenia. Int J Lab Hematol 2010; 32:E96–E105. Sella R, Flomenblit L, Goldstein I, Kaplinsky C. Detection of Anti-Neutrophil Antibodies in Autoimmune Neutropenia of Infancy: A Multicenter Study. Isr Med Assoc J 2010; 12:91–96, 2010 Feb.

Physiological role of IL-8 and its receptors Ghadimi D, de Vrese M, Heller KJ, Schrezenmeir J. Effect of Natural Commensal-Origin DNA on Toll-like Receptor 9 (TLR9) Signaling Cascade, Chemokine IL-8 Expression, and Barrier Integritiy of Polarized Intestinal Epithelial Cells. Inflamm Bowel Dis 2010; 16:410–427. Meis S, Hamacher A, Hongwiset D, Marzian C, et al. NF546 [4,4 ’-(Carbonylbis(imino-3,1-phenylene-carbonylimino3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylenealpha,alpha ’-diphosphonic Acid) Tetrasodium Salt] Is a Non-Nucleotide P2Y(11) Agonist and Stimulates Release of Interleukin-8 from Human Monocyte-Derived Dendritic Cells. J Pharmacol Exp Ther 2010; 332:238–247.

Clinical spectrum and molecular pathophysiology of Shwachman– Diamond syndrome Review: (pp. 30–35) Burroughs L, Woolfrey A, Shimamura A. Shwachman– Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment. Hematol Oncol Clin North Am 2009; 23:233–248. [03] de Oliveira JF, Sforc¸a ML, Blumenschein TMA, et al. Structure, dynamics, and RNA interaction analysis of the human SBDS protein. J Mol Biol 2009; 396:1053–1069. [31] Kerr EN, Ellis L, Dupuis A, et al. The behavioral phenotype of school-age children with Shwachman–Diamond syndrome indicates neurocognitive dysfunction with loss of Shwachman–Bodian–Diamond syndrome gene function. J Pediatr 2010; 156:433-438.e1. [21] Maserati E, Pressato B, Valli R, et al. The route to development of myelodysplastic syndrome/acute myeloid leukaemia in Shwachman–Diamond syndrome: the role of ageing, karyotype instability, and acquired chromosome anomalies. Br J Haematol 2009; 145:190–197. [20] Moore JBIV, Farrar JE, Arceci RJ, et al. Distinct ribosome maturation defects in yeast models of Diamond– Blackfan anemia and Shwachman–Diamond syndrome. Haematologica 2009; 95:57–64. [33] Raaijmakers MHGP, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464:852–857. [40] Toiviainen-Salo S, Durie PR, Numminen K, et al. The natural history of Shwachman–Diamond syndrome-associated liver disease from childhood to adulthood. J Pediatr 2009; 155:807-811.e2. [22]

Advances in the diagnosis and treatment of chronic granulomatous disease Review: (pp. 36–41) Aguilera DG, Tomita T, RajaramV, FangusaroJ,et al. Glioblastoma Multiforme in a Patient With Chronic Granulomatous Disease Treated With Subtotal Resection, Radiation, and Thalidomide Case Report of a Long-term Survivor. J Pediatr Hematol Oncol 2009; 31:965–969.

Ardeniz O, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Clin Immunol 2009; 133:198–207. Elhasid R, Rowe JM. Hematopoetic Stem Cell Transplantation in Neutrophil Disorders: Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency and Chronic Granulomatous Disease [Review]. Clin Rev Allergy Immunol 2010; 38:61–67. Feld JJ, Hussain N, Wright EC, et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology 2008; 134:1917–1926. [20] Fernandez-Boyanapalli R, Frasch SC, Riches DW, et al. PPAR{gamma} activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood 2010 [Epub ahead of print]. [19] Goussetis E, Konialis CP, Peristeri I, Kitra V, et al. Successful Hematopoietic Stem Cell Transplantation in 2 Children with X-Linked Chronic Granulomatous Disease from Their Unaffected HLA-Identical Siblings Selected Using Preimplantation Genetic Diagnosis Combined with HLA Typing. Biol Blood Marrow Transplant 2010; 16:344– 349. Jones LB, McGrogan P, Flood TJ, et al. Chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008; 152:211–218. [57] Lee PP, Chan KW, Jiang L, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J 2008; 27:224–230. [14] Martin A, Marques L, Soler-Palacin P, et al. Visceral leishmaniasis associated hemophagocytic syndrome in patients with chronic granulomatous disease. Pediatr Infect Dis J 2009; 28:753–754. [16] Matute JD, Arias AA, Wright NA, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009; 114:3309–3315. [32] No Authors Given. Abstracts of EBMT (European Group for Blood and Marrow Transplantation) 2009. March 29– April 1, 2009. Goteborg, Sweden. Bone Marrow Transplant 2009; 43(Suppl 1):S75. [60] Notarangelo LD, Casanova JL. Primary immunodeficiencies: increasing market share. Curr Opin Immunol 2009; 21:461–465. Patiroglu T, Unal E, Yikilmaz A, Koker MY, et al. Atypical presentation of chronic granulomatous disease in an adolescent boy with frontal lobe located Aspergillus abscess mimicking intracranial tumor. Childs Nerv Syst 2010; 26:149–154. Reichenbach J, Lopatin U, Mahlaoui N, Beovic B, et al. Actinomyces in Chronic Granulomatous Disease: An Emerging and Unanticipated Pathogen. Clin Infect Dis 2009; 49:1703–1710. Reichenbach J, Lopatin U, Mahlaoui N, et al. Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis 2009; 49:1703– 1710. [10] Sherif R, Segal BH. Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr Opin Pulm Med 2010; 16: 242–250. Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009; 145:73–83. [53] Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:198–204. [65] Van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4:e5234. [56]

Clinical spectrum, pathophysiology and treatment of the Wiskott– Aldrich syndrome Review: (pp. 42–48) Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010; 115:3231–3238. [07]


66 Myeloid biology Neutropenia and other hematological complications of tyrosine kinase inhibitor therapy Albert MH, Bittner TC, Nonoyama S, Notarangelo LD, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010; 115:3231–3238. Astrakhan A, Ochs HD, Rawlings DJ. Wiskott–Aldrich syndrome protein is required for homeostasis and function of invariant NKT cells. J Immunol 2009; 182:7370–7380. [31] Beel K, Cotter MM, Blatny J, et al. A large kindred with X-linked neutropenia with an I294T mutation of the Wiskott–Aldrich syndrome gene. Br J Haematol 2009; 144:120–126. [14] Blundell MP, Bouma G, Metelo J, Worth A, et al. Phosphorylation of WASp is a key regulator of activity and stability in vivo. Proc Natl Acad Sci USA 2009; 106:15738–15743. Bosticardo M, Marangoni F, Aiuti A, et al. Recent advances in understanding the pathophysiology of Wiskott–Aldrich syndrome. Blood 2009; 113:6288–6295. [33] Burns SO, Killock DJ, Moulding DA, et al. A congenital activating mutant of WASp causes altered plasma membrane topography and adhesion under flow in lymphocytes. Blood 2010; 115:5355–5365. [17] Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126:602–610. [53] Horino T, Matsumoto T, Ishikawa H, Kimura S, et al. Interleukin1 deficiency in combination with macrophage depletion increases susceptibility to Pseudomonas aeruginosa bacteremia. Microbiol Immunol 2009; 53:502–511. Locci M, Draghici E, Marangoni F, et al. The Wiskott–Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med 2009; 206:735–742. [30] Mantovani J, Charrier S, Eckenberg R, et al. Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott–Aldrich syndrome. J Gene Med 2009; 11:645–654. [58] Marangoni F, Bosticardo M, Charrier S, et al. Evidence for long term efficacy and safety of gene therapy for Wiskott– Aldrich syndrome in preclinical models. Mol Ther 2009; 17:1073–1082. [56] Nikolov NP, Shimizu M, Cleland S, et al. Systemic autoimmunity and defective Fas ligand secretion in the absence of the Wiskott–Aldrich syndrome protein. Blood 2010; 116:740–747. [47] Shcherbina A, Cooley J, Lutskiy MI, et al. WASP plays a novel role in regulating platelet responses dependent on alphaIIbbeta3 integrin outside-in signalling. Br J Haematol 2009; 148:416–427. [42] Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol 2010; 10:182–192. [32] Thrasher AJ, Burns SO. WASP: a key immunological multitasker [Review]. Nat Rev Microbiol 2010; 10(3):182192,:182–192. Trifari S, Scaramuzza S, Catucci M, Ponzoni M, et al. Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: Analysis of function and distribution in lymphoid organs. J Allergy Clin Immunol 2010; 125:439–448. Westerberg LS, Meelu P, Baptista M, et al. Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes. J Exp Med 2010; 207:1145–1152. [16] Zhang ZY, Xiao HQ, Jiang LP, Zhou Y, et al. Analysis of clinical and molecular characteristics of Wiskott-Aldrich syndrome in 24 patients from 23 unrelated Chinese families. Pediatr Allergy Immunol 2010; 21:522–532.

Neutropenia associated with rituximab therapy Review: (pp. 49–54) Barr PM, Fu PF, Lazarus HM, Horvath N, et al. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol 2009; 147:89–96. Dunleavy K, Tay K, Wilson WH. Rituximab-Associated Neutropenia. Semin Hematol 2010; 47:180–186. Lai GG, Lim ST, Tao M, et al. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol 2009; 84:414–417. [14] Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143–2152. [08] Sellier-Leclerc AL, Macher MA, Loirat C, Guerin V, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25:1109– 1115.

Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphoma. J Clin Oncol 2010; 28:279–284. [34]

Advances in diagnosis and treatment of large granular lymphocyte syndrome Review: (pp. 55–62) Bareau B, Rey J, Hamidou M, et al. Analysis of the french LGL leukemia cohort: report on 229 cases. Heamatologica 2010; 95:1534–1541. [11] Duarte AF, Nogueira A, Mota A, Baudrier T, et al. Leg ulcer and thigh telangiectasia associated with natural killer cell CD56(-) large granular lymphocyte leukemia in a patient with pseudo-Felty syndrome. J Am Acad Dermatol 2010; 62:496–501. Fortune AF, Kelly K, Sargent J, O’Brien D, et al. Large granular lymphocyte leukemia: natural history and response to treatment. Leuk Lymphoma 2010; 51:839– 845. Gattazzo C, Miorin M, Scquizzato E, et al. Lack of expression of inhibitory KIR3DL1 receptor in patients with NK-type lymphoproliferative disease of granular lymphocytes. Haematologica 2010; 95:1722–1729. [72] Gozzetti A, Fabbri A, Oliva S, Marchini E, et al. Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2010; 10:. Kuehnhardt D, Hannemann M, Schmidt B, Heider U, et al. Therapeutic implication of BAL in patients with neutropenia. Ann Hematol 2009; 88:1249–1256. Miyazaki K, Ohsaka M, Suzuki Y, Danbara M, et al. CD20Positive T-Cell Large Granular Lymphocyte Leukemia: Case Report and Review of the Literature. Intern Med 2009; 48:1443–1447. Mohan SR, Clemente MJ, Afable M, et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8þ large granular lymphocyte leukemia. Haematologica 2009; 94:1407–1414. [85] Morice WG, Jevremovic D, Olteanu H, et al. Chronic lymphoproliferative disorder of natural killer cells: a distinct entity with subtypes correlating with normal natural killer cell subsets. Leukemia 2010; 24:881–884. [49] Moura J, Rodrigues J, Santos AH, et al. Chemokine receptor repertoire reflects mature T-cell lymphoproliferative disorder clinical presentation. Blood Cells Mol Dis 2009; 42:57–63. [25] Shah MV, Zhang R, Loughran Jr TP. Never say die: survival signaling in large granular lymphocyte leukemia. Clin Lymphoma Myeloma 9(Suppl 3)2009:S244–S253. [60] Viny A, Clemente MJ, Jasek M, et al. MICA polymorphism identified by whole genome array associated with NKG2D-mediated cytotoxicity in T-cell large granular lymphocyte leukemia. Haematologica 2010; 95:1713– 1721. [57] Yang J, Liu X, Nyland SB, et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010; 115:51–60. [65] Zambello R, Semenzato G. Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica 2009; 94:1341–1345.

Infectious mononucleosis and return to play Ahmad UA, Anari S. Infectious mononucleosis screening in quinsy patients. Eur Arch Otorhinolaryngol 2010; 267:113–115. Ascherio A, Bar-Or A. EBV and brain matter(s)? Neurology 2010; 74:1092–1095. Berth M, Bosmans E. Comparison of Three Automated Immunoassay Methods for the Determination of EpsteinBarr Virus-Specific Immunoglobulin M. Clin Vaccine Immunol 2010; 17:559–563, 2010 Apr. Chang FR, Hsieh YC, Chang YF, Lee KH, et al. Inhibition of the Epstein-Barr virus lytic cycle by moronic acid. Antiviral Res 2010; 85:490–495. Darteyre S, Ludwig C, Jeziorski E, Schved JF, et al. Hemophagocytic lymphohistiocytosis and Epstein-Barr virus infection in children [French]. Med Mal Infect 2010; 40:18–26.

De Falco G, Antonicelli G, Onnis A, Lazzi S, et al. Role of EBV in microRNA dysregulation in Burkitt lymphoma [Review]. Semin Cancer Biol 2009; 19:401–406. Gu AD, Lu LX, Xie YB, Chen LZ, et al. Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology - art. no. 73. J Transl Med 2009:73. Han XY, Hellerstedt BA, Koller CA. Postsplenectomy Cytomegalovirus Mononucleosis is a Distinct Clinicopathologic Syndrome. Am J Med Sci 2010; 339:395–399. Hoshino Y, Katano H, Zou P, Hohman P, et al. Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers. J Virol 2009; 83:11857–11861. Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, et al. TollLike Receptor Agonists Synergistically Increase Proliferation and Activation of B Cells by Epstein-Barr Virus. J Virol 2010; 84:3612–3623. Kagoya Y, Hangaishi A, Takahashi T, Imai Y, et al. High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis. Int J Hematol 2010; 91:326–327. Lopez SZ, Vicario JM, Lerin FJ, Fernandez A, et al. Epstein-Barr Virus Myocarditis as the First Symptom of Infectious Mononucleosis. Intern Med 2010; 49:569– 571. Macsween KF, Higgins CD, McAulay KA, Williams H, et al. Infectious Mononucleosis in University Students in the United Kingdom: Evaluation of the Clinical Features and Consequences of the Disease. Clin Infect Dis 2010; 50:699–706. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, et al. The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBVPK, but Not the Thymidine Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral Production. J Virol 2010; 84:4534–4542. Nagy N, Klein E. Deficiency of the proapoptotic SAP function in X-linked lymphoproliferative disease aggravates EpsteinBarr virus (EBV) induced mononucleosis and promotes lymphoma development. Immunol Lett 2010; 130:13–18. Nourse JP, Jones K, Dua U, Runnegar N, et al. Fulminant Infectious Mononucleosis and Recurrent Epstein-Barr Virus Reactivation in an Adolescent. Clin Infect Dis 2010; 50:E34–E37. Pagidipati N, Obstein KL, Rucker-Schmidt R, Odze RD, et al. Acute Hepatitis Due to Epstein-Barr Virus in an Immunocompetent Patient. Dig Dis Sci 2010; 55:1182– 1185. Park JM, Il Shin J, Lee JS, Jang YH, et al. False Positive Immunoglobulin M Antibody to Cytomegalovirus in Child with Infectious Mononucleosis Caused by Epstein-Barr Virus Infection. Yonsei Medical Journal 2009; 50:713– 716. Pohl D. Epstein-Barr virus and multiple sclerosis. J Neurol Sci 2009; 286:62–64. Pohl D, Rostasy K, Jacobi C, Lange P, et al. Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis. J Neurol 2010; 257:212–216. Rees L, Tizard EJ, Morgan AJ, Cubitt WD, et al. A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation. Transplantation 2009; 88:1025–1029. Sargsyan SA, Shearer AJ, Ritchie AM, Burgoon MP, et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010; 74:1127–1135. Sauce D, Larsen M, Abbott RJM, Hislop AD, et al. Upregulation of Interleukin 7 Receptor Alpha and Programmed Death 1 Marks an Epitope-Specific CD8(+) T-Cell Response That Disappears following Primary Epstein-Barr Virus Infection. J Virol 2009; 83:9068–9078. Xie JL, Zhou XG. Infectious mononucleosis-like lesions, a rare manifestation of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2010; 51:944–946.

Neutropenia and other hematological complications of tyrosine kinase inhibitor therapy Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment [Review]. Curr Opin Rheumatol 2010; 22:330–335. Maschmeyer G, Beinert T, Buchheidt D, Cornely OA, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology [Review]. Eur J Cancer 2009; 45:2462–2472.


Myeloid biology Advances in therapeutics 67 Quintas-Cardama A, Santos FPD, Kantarjian H, O’Brien S, et al. Dynamics and Management of Cytopenias Associated With Dasatinib Therapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Imatinib Failure. Cancer 2009; 115:3935–3943. Rhee CK, Kang JY, Kim YH, Kim JW, et al. Risk factors for acute respiratory distress syndrome during neutropenia recovery in patients with hematologic malignancies - art. no. R173. Crit Care 2009; 13:R173.

Myelopoiesis Barjaktarevic I, Maletkovic-Barjaktarevic J, Kamani NR, Vukmanovic S. Altered functional balance of Gfi-1 and Gfi-1b as an alternative cause of reticular dysgenesis? Med Hypotheses 2010; 74:445–448. Fadeel B, Grzybowska E. HAX-1: A multifunctional protein with emerging roles in human disease [Review]. Biochim Biophys Acta - Gen Sub 2009; 1790:1139– 1148. Faiyaz-Ul-Haque M, Al-Jefri A, Al-Dayel F, Bhuiyan JAKM, et al. A novel HAX1 gene mutation in severe congenital neutropenia (SCN) associated with neurological manifestations. Eur J Pediatr 2010; 169:661–666. Faiyaz-Ul-Haquea M, Al-Jefric A, Abalkhail HA, Toulimat M, et al. A novel missense mutation in the HAX1 gene in severe congenital neutropenia patients (Kostmann disease). Clin Genet 2009; 76:569–572. Geest CR, Buitenhuis M, Laarhoven AG, Bierings MB, et al. p38 MAP Kinase Inhibits Neutrophil Development Through Phosphorylation of C/EBP alpha on Serine 21. Stem Cells 2009; 27:2271–2282. Katsumori T, Yoshino H, Hayashi M, Takahashi K, et al. Inductive Potential of Recombinant Human Granulocyte Colony-Stimulating Factor to Mature Neutrophils from XIrradiated Human Peripheral Blood Hematopoietic Progenitor Cells. Biological & Pharmaceutical Bulletin 2009; 32:1849–1853. Neyt P, Jorissen M. Diagnosis of isolated sphenoid lesions. BENT 2009; 5:213–224. Whichard ZL, Sarkar CA, Kimmel M, Corey SJ. Hematopoiesis and its disorders: a systems biology approach [Review]. Blood 2010; 115:2339–2347. Wolfrom CM, Levy V, Deschatrette J. Neutropenia dynamics in a case of T-LGL lymphoproliferation illustrate rapid turnover of granulocyte progenitors. Cell Prolif 2010; 43:326–332.

Pattern recognition receptors Wang JP, Zhang Y, Wei X, Li J, et al. Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS 2010; 118:261–270.

Neutropenia Adamiak T, Gheller-Rigoni A, Arca M, Grossman W, et al. Perianal Disease as the Initial Presentation of Autoimmune Neutropenia. J Pediatr Gastroenterol Nutr 2010; 50:99–102. Arostegui JI, de Toledo JS, Pascal M, Garcia C, et al. A novel G6PC3 homozygous 1-bp deletion as a cause of severe congenital neutropenia. Blood 2009; 114:1718–1719. Avabratha KS, Rau ATK, Venkataravanamma P, Rau A. Significance of C-reactive Protein During Febrile Neutropenia in Pediatric Malignancies. Indian Pediatr 2009; 46:797–799. Bernet C, De Brabant F, Gonzalez M, Jung B, et al. Pelvic actinomycosis: A misleading picture [French]. Ann Fr Anest Reanim 2010; 29:50–52. Borbe R, Weisel K, Sachs UJH, Steinert T. Severe Psychotic Disorder and Agranulocytosis - A Therapeutic Dilemma. Pharmacopsychiatry 2009; 42:284–285. Cloutier RL. Neutropenic Enterocolitis. Emerg Med Clin North Am 2009; 27:415–. Cordonnier C, Schwarzinger M. Empirical versus Preemptive Antifungal Therapy for Fever during Neutropenia Reply. Clin Infect Dis 2009; 49:1139–1140. Eliopoulos DG, Mavroudi I, Pontikoglou C, Ximeri M, et al. The509C/T polymorphism of transforming growth factor-beta 1 is associated with increased risk for development of chronic idiopathic neutropenia. Eur J Haematol 2009; 83:535–540. Gunzer K, Clarisse B, Lheureux S, Delcambre C, et al. Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data. Expert Opin Biol Ther 2010; 10:615–630.

Gupta A, Swaroop C, Agarwala S, Pandey RM, et al. Randomized Control Trial Comparing Oral Amoxicillinclavulanate and Ofloxacin With Intravenous Ceftriaxone and Amikacin as Outpatient Therapy in Pediatric Low-risk Febrile Neutropenia. J Pediatr Hematol Oncol 2009; 31:635–641. Hakim H, Flynn PM, Knapp KM, Srivastava DK, et al. Etiology and Clinical Course of Febrile Neutropenia in Children With Cancer. J Pediatr Hematol Oncol 2009; 31:623– 629. Hakim H, Flynn PM, Srivastava DK, Knapp KM, et al. Risk Prediction in Pediatric Cancer Patients With Fever and Neutropenia. Pediatr Infect Dis J 2010; 29:53– 59. Hummel M, Warga C, Hof H, Hehlmann R, et al. Diagnostic yield of blood cultures from antibiotic-naive and antibiotically treated patients with haematological malignancies and high-risk neutropenia. Scand J Infect Dis 2009; 41:650–655. Jeddi R, Achour M, Ben Amor R, Aissaoui L, et al. Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology 2010; 15:28– 32. Kassam A, Chan AKC, Dzolganovski B, Constantin J, et al. No Association Between Protein C Levels and Bacteremia in Children With Febrile Neutropenia. J Pediatr Hematol Oncol 2009; 31:647–650. Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 2009; 101:S6–S10. Kim JJ, Park JY, Kim DY, Kim JH, et al. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer? Acta Obstet Gynecol Scand 2010; 89:623– 628. Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, et al. Evaluation of Caspofungin or Micafungin as Empiric Antifungal Therapy in Adult Patients With Persistent Febrile Neutropenia: A Retrospective, Observational, Sequential Cohort Analysis. Clin Ther 2010; 32:637– 648. Kuhn P, Messer J, Paupe A, Espagne S, et al. A Multicenter, Randomized, Placebo-Controlled Trial of Prophylactic Recombinant Granulocyte-Colony Stimulating Factor in Preterm Neonates with Neutropenia. J Pediatr 2009; 155:324–330. Kumpulainen EJ, Hirvikoski PP, Johansson RT. Neutropenia during adjuvant chemotherapy of breast cancer is not a predictor of outcome. Acta Oncol 2009; 48:1204– 1206. Lamoth F, Buclin T, Pascual A, Calandra T, et al. Imipenem underdosing as a cause of persistent neutropenic fever? J Antimicrob Chemother 2009; 63:665–667. Lamoth F, Buclin T, Pascual A, Calandra T, et al. Imipenem underdosing as a cause of persistent neutropenic fever? J Antimicrob Chemother 2009; 64:665–667. Leonardi S, Vitaliti G, La Rosa M. Recurrent Febrile Infections and Neutropenia in a Child With Silent Celiac Disease. Clin Pediatr (Phila) 2010; 49:146–149. Lima CSP, Lourenco GJ, Lorand-Metze I, Nascimento H, et al. No contribution of GSTM1 and GSTT1 null genotypes to the risk of neutropenia due to benzene exposure in Southeastern Brazil. Genetics and Molecular Biology 2009; 32:709–711. Liu CI, Hsiao CH, Wu JT, Tsai TF. Sweet syndrome with histiocytoid infiltrate and neutropenia: A rare combination. J Am Acad Dermatol 2009; 61:882–888. Maertens JA, Madero L, Reilly AF, Lehrnbecher T, et al. A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia. Pediatr Infect Dis J 2010; 29:415–420. Mangan JK, Russell JE. Profound neutropenia resulting from metyrapone-induced adrenal crisis. Am J Hematol 2009; 84:773. Marr KA, Leisenring W, Bow E. Empirical versus Preemptive Antifungal Therapy for Fever during Neutropenia. Clin Infect Dis 2009; 49:1138–1139. Mayordomo JI, Lopez A, Vinolas N, Castellanos J, et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009; 25:2533–2542. Meckler G, Lindemulder S. Fever and Neutropenia in Pediatric Patients with Cancer [Review]. Emerg Med Clin North Am 2009; 27:525–. Melendez E, Harper MB. Risk of Serious Bacterial Infection in Isolated and Unsuspected Neutropenia. Acad Emerg Med 2010; 17:163–167. Osband AJ, Laskow DA, Berkowicz T, Mann RA. Fever and Neutropenia Following Simultaneous Pancreas-Kidney Transplantation. Am J Kidney Dis 2009; 54:XXXV– XXXVII.

Parikh SA, Kantarjian HM, Richie MA, Cortes JE, et al. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma 2010; 51:269– 274. Poele EMT, Tissing WJE, Kamps WA, de Bont ESJM. Risk assessment in fever and neutropenia in children with cancer: What did we learn? [Review]. Crit Rev Oncol/ Hematol 2009; 72:45–55. Quillen K, Wong E, Scheinberg P, Young NS, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica 2009; 94:1661–1668. Rettenbacher MA, Hofer A, Kemmler G, Fleischhacker WW. Neutropenia Induced by Second Generation Antipsychotics: A Prospective Investigation. Pharmacopsychiatry 2010; 43:41–44. Sakaguchi S, Garcia-Bournissen F, Kim R, Schwarz UI, et al. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Arch Dis Child 2009; 94:981–982. Sato E, Ikeda K, Yoshida H, Kusuki S, et al. Septic pulmonary embolism from Staphylococcus haemolyticus during neutropenia. Pediatr Int 2010; 52:e121–e124. Schulz C, Boeck S, Heinemann V, Stemmler HJ. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? [Review]. Anticancer Drug 2009; 20:867–879. Seftel MD. Controversies in the management of fever in the neutropenic cancer patient. Transfus Apheresis Sci 2010; 42:151–156. Severin JA, Mertaniasih NM, Kuntaman K, Lestari ES, et al. Molecular characterization of extended-spectrum betalactamases in clinical Escherichia coli and Klebsiella pneumoniae isolates from Surabaya, Indonesia. J Antimicrob Chemother 2010; 65:465–469. Sharma G, Nesin M, Feuerstein M, Bussel JB. Maternal and Neonatal Characteristics Associated with Neonatal Neutropenia in Hypertensive Pregnancies. Am J Perinatol 2009; 26:683–689. Sheen JM, Kuo HC, Yu HR, Huang EY, et al. Prolonged Acquired Neutropenia in Children. Pediatric Blood Cancer 2009; 53:1284–1288. Volpi L, Roversi G, Colombo EA, Leijsten N, et al. Targeted Next-Generation Sequencing Appoints C16orf57 as Clericuzio-Type Poikiloderma with Neutropenia Gene. Am J Hum Genet 2010; 86:72–76. Vrielink H, Meijer B, van ’t Ende E, Ball LM, et al. Granulocyte transfusions for pediatric patients and the establishment of national treatment guidelines and donor registry. Transfus Apheresis Sci 2009; 41:73–76. Vural S, Erdem E, Gulec SG, Yildirmak Y, et al. Imipenemcilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int 2010; 52:262–267. Wehbe AM, Johannsson B, Raife TJ, Bleile M, et al. Severe autoimmune neutropenia associated with acute autoimmune hepatitis. Int J Hematol 2010; 91:673–678. Wiens MO, Son WK, Ross C, Hayden M, et al. Cocaine adulterant linked to neutropenia. Can Med Assoc J 2009; 182:57–59, 2009 Jan 12..

Transcriptional regulation of myeloid cells Pal R, Monaghan SA, Hassett AC, Mapara MY, et al. Immunomodulatory derivatives induce PU.1 downregulation, myeloid maturation arrest, and neutropenia. Blood 2010; 115:605–614.

Advances in therapeutics Adiga GU, Elkadi D, Malik SK, Fitzpatrick JD, et al. Abdominal Aortitis after Use of Granulocyte Colony-Stimulating Factor. Clin Drug Invest 2009; 29:821–825. Bal AM. The echinocandins: three useful choices or three too many? [Review]. Int J Antimicrob Agents 2010; 35:13– 18. Cohen-Wolkowiez M, Moran C, Benjamin DK, Smith PB. Pediatric antifungal agents [Review]. Curr Opin Infect Dis 2009; 22:553–558. Fioredda F, Calvillo M, Lanciotti M, Lanza T, et al. Pegfilgrastim in Children With Severe Congenital Neutropenia. Pediatric Blood Cancer 2010; 54:465– 467. Fox E, Widemann BC, Hawkins DS, Jayaprakash N, et al. Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas. Clin Cancer Res 2009; 15:7361–7367.


68 Myeloid biology Congenital myeloid diseases Gomez L, Estrada C, Gomez I, Marquez M, et al. Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial. Eur J Clin Microbiol Infect Dis 2010; 29:417–427. Inparajah M, Wong C, Sibbald C, Boodhan S, et al. Once-Daily Gentamicin Dosing in Children with Febrile Neutropenia Resulting from Antineoplastic Therapy. Pharmacotherapy 2010; 30:43–51. Kanai M, Morita S, Matsumoto S, Nishimura T, et al. A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Ann Oncol 2009; 20:1397–1401. Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 2009; 101:S6–S10. Kobayashi K, Ogasawara M, Kiyama Y, Miyazono T, et al. Successful Voriconazole Treatment of Invasive Pulmonary Aspergillosis in a Patient with Acute Biphenotypic Leukemia. Acta Med Okayama 2009; 63:213–216. Kuhn P, Messer J, Paupe A, Espagne S, et al. A Multicenter, Randomized, Placebo-Controlled Trial of Prophylactic Recombinant Granulocyte-Colony Stimulating Factor in Preterm Neonates with Neutropenia. J Pediatr 2009; 155:324–330. MacNicholas R, Norris S. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents [Review]. Aliment Pharmacol Ther 2010; 31:929–937. Mebis J, Goossens H, Berneman ZN. Antibiotic Management of Febrile Neutropenia: Current Developments and Future Directions [Review]. J Chemother 2010; 22:5–12. Mebis J, Goossens H, Berneman ZN. Cefepime and mortality. Lancet Infect Dis 2009; 9:585–586. Pai V, Fernandez SA, Laudick M, Rosselet R, et al. Delayed Administration of Filgrastim (G-CSF) Following Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) in Pediatric Patients Does Not Change Time to Neutrophil Engraftment and Reduces Use of G-CSF. Pediatric Blood Cancer 2010; 54:728–733. Palumbo A, Bringhen S, Bruno B, Falcone AP, et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010; 115:1873–1879. Patel RA, Gallagher JC. Drug Fever [Review]. Pharmacotherapy 2010; 30:57–69. Quillen K, Wong E, Scheinberg P, Young NS, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica 2009; 94:1661–1668. Renwick W, Pettengell R, Green M. Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy Twenty Years of Clinical Experience [Review]. Biodrugs 2009; 23:175–186. Roy-Ghanta S, Orange JS. Use of Cytokine Therapy in Primary Immunodeficiency [Review]. Clin Rev Allergy Immunol 2010; 38:39–53. Scholz M, Ackermann M, Engel C, Emmrich F, et al. A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia. Cell Prolif 2009; 42:813–822. Scholz M, Engel C, Apt D, Sankar SL, et al. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative MaxyG34 and pegfilgrastim in rats. Cell Prolif 2009; 42:823– 837. Scott WR, Silberstein L, Flatley R, Ardeshna KM, et al. Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption. Br J Dermatol 2009; 161:717– 719. Sehouli J, Goertz A, Steinle T, Dubois R, et al. Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a costeffectiveness analysis for Germany [German]. Dtsch Med Wochenschr 2010; 135:385–389. Vural S, Erdem E, Gulec SG, Yildirmak Y, et al. Imipenemcilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia. Pediatr Int 2010; 52:262–267.

Biomarkers, diagnostic and prognostic indicators Bononi A, Lanza F, Ferrari L, Gusella M, et al. Predictive Value of Hematological and Phenotypical Parameters on Postchemotherapy Leukocyte Recovery. Cytom Part BClin Cytom 2009; 76B:. Breccia M, Latagliata R, Cannella L, Carmosino I, et al. Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. Leuk Lymphoma 2010; 51:783–788.

Carnino L, Betteto S, Loiacono M, Chiappella A, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol 2010; 136:611–615. Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, et al. The Emerging Role of Biomarkers in Diabetic and Hypertensive Chronic Kidney Disease. Curr Diabetes Rep 2010; 10:37–42. Daneshmandi S, Ghasemi A, Pourfathollah AA. IL-6-174G/C Promoter Polymorphism in Acute Appendicitis. Labmedicine 2009; 40:600–603. Eliopoulos DG, Mavroudi I, Pontikoglou C, Ximeri M, et al. The509C/T polymorphism of transforming growth factor-beta 1 is associated with increased risk for development of chronic idiopathic neutropenia. Eur J Haematol 2009; 83:535–540. Huang M, Hu ZP, Chang W, Ou DM, et al. The Growth Factor Independence-1 (Gfi1) Is Overexpressed in Chronic Myelogenous Leukemia. Acta Haematol 2010; 123:1–5. Kallinich T, Wittkowski H, Keitzer R, Roth J, et al. Neutrophilderived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis 2010; 69:677–682. Khandanpour C, Thiede C, Valk PJM, Sharif-Askari E, et al. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. Blood 2010; 115:2462–2472. Lane SW, Hassell P, Kennedy GA, Fung YL, et al. Characterization of the bone marrow immunofluorescence test in childhood autoimmune neutropenia. Int J Lab Hematol 2009; 31:567–571. Malcov M, Reches A, Ben-Yosef D, Cohen T, et al. Resolving a genetic paradox throughout preimplantation genetic diagnosis for autosomal dominant severe congenital neutropenia. Prenat Diagn 2010; 30:207–211. Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Malyszko JS, et al. Urinary and Serum Biomarkers after Cardiac Catheterization in Diabetic Patients with Stable Angina and without Severe Chronic Kidney Disease. Ren Fail 2009; 31:910–919. Mauri T, Bellani G, Patroniti N, Coppadoro A, et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med 2010; 36:621–629. Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: Practical consideration for clinicians [Review]. Gastroenterol Clin Biol 2009; 33:S158–S173. Mikulska M, Raiola AM, Bruno B, Furfaro E, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44:361– 370. Moon JM, Chun BJ. Predicting the complicated neutropenic fever in the emergency department. Emerg Med J 2009; 26:802–806. Moriates C, Maisel A. The Utility of Biomarkers in Sorting Out the Complex Patient [Review]. Am J Med 2010; 123:393–399. Nguyen XD, Flesch B, Sachs UJ, Kroll H, et al. Rapid screening of granulocyte antibodies with a novel assay: flow cytometric granulocyte immunofluorescence test. Transfusion 2009; 49:2700–2708. Park Y, Kim DS, Park SJ, Seo HY, et al. The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. Leuk Res 2010; 34:294–300. Velez NF, Saavedra-Lauzon AP. Toxic Exanthems in the Adult Population [Review]. Am J Med 2010; 123:296–303. Wimazal F, Germing U, Kundi M, Noesslinger T, et al. Evaluation of the Prognostic Significance of Eosinophilia and Basophilia in a Larger Cohort of Patients With Myelodysplastic Syndromes. Cancer 2010; 116:2372– 2381. Wolff M, Kredel S, Haasen D, Wiedenmann J, et al. High Content Screening of CXCR2-Dependent Signalling Pathways. Comb Chem High Throughput Scr 2010; 13:3–15.

Congenital myeloid diseases Aguilar-Guisado M, Espigado I, Cordero E, Noguer M, et al. Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplant 2010; 45:159–164. Arostegui JI, de Toledo JS, Pascal M, Garcia C, et al. A novel G6PC3 homozygous 1-bp deletion as a cause of severe congenital neutropenia. Blood 2009; 114:1718–1719. Aytekin C, Germeshausen M, Tuygun N, Tanir G, et al. Eponym Kostmann disease [Review]. Eur J Pediatr 2010; 169:657–660.

Aytekin C, Germeshausen M, Tuygun N, Tanir G, et al. Kostmann disease with developmental delay in three patients. Eur J Pediatr 2010; 169:759–762. Barjaktarevic I, Maletkovic-Barjaktarevic J, Kamani NR, Vukmanovic S. Altered functional balance of Gfi-1 and Gfi-1b as an alternative cause of reticular dysgenesis? Med Hypotheses 2010; 74:445–448. Boztug K, Klein C. Novel genetic etiologies of severe congenital neutropenia [Review]. Curr Opin Immunol 2009; 21:472– 480. Carlsson G, Elinder G, Malmgren H, Trebinska A, et al. Compound Heterozygous HAX1 Mutations in a Swedish Patient With Severe Congenital Neutropenia and No Neurodevelopmental Abnormalities. Pediatric Blood Cancer 2009; 53:1143–1146. Chou JY, Jun HS, Mansfield BC. Neutropenia in type Ib glycogen storage disease. Curr Opin Hematol 2010; 17:36–42. D’Costa J, Mansfield SG, Humeau LM. Lentiviral vectors in clinical trials: Current status [Review]. Curr Opin Mol Ther 2009; 11:554–564. Dale DC. Recent progress in understanding the congenital neutropenias. Curr Opin Hematol 2010; 17:1–2. Faiyaz-Ul-Haquea M, Al-Jefric A, Abalkhail HA, Toulimat M, et al. A novel missense mutation in the HAX1 gene in severe congenital neutropenia patients (Kostmann disease). Clin Genet 2009; 76:569–572. Feder HM, Salazar JC. A clinical review of 105 patients with PFAPA (a periodic fever syndrome) [Review]. Acta Paediatr 2010; 99:178–184. Freeman AF, Holland SM. Antimicrobial prophylaxis for primary immunodeficiencies [Review]. Curr Opin Allergy Clin Immunol 2009; 9:525–530. Germeshausen M, Kratz CP, Ballmaier M, Welte K. RAS and CSF3R mutations in severe congenital neutropenia. Blood 2009; 114:3504–3505. Goussetis E, Konialis CP, Peristeri I, Kitra V, et al. Successful Hematopoietic Stem Cell Transplantation in 2 Children with X-Linked Chronic Granulomatous Disease from Their Unaffected HLA-Identical Siblings Selected Using Preimplantation Genetic Diagnosis Combined with HLA Typing. Biol Blood Marrow Transplant 2010; 16:344– 349. Hsiao SC, Lin JF, Chuang MT, Lee YA, et al. Retrospectively Comparative Evaluation of the First- and Second-Line Chemotherapy With Campto and Oxaliplatin Combined With Oral Tegafur/Uracil (UFT)/Leucovorin (LV) in Patients With Metastatic Colorectal Cancer. Int Surg 2009; 94:298–303. Khandanpour C, Thiede C, Valk PJM, Sharif-Askari E, et al. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. Blood 2010; 115:2462–2472. Klein C. Molecular basis of congenital neutropenia. Haematologica 2009; 94:1333–1336. Klein C, Welte K. Genetic Insights into Congenital Neutropenia [Review]. Clin Rev Allergy Immunol 2010; 38:68–74. Lanciotti M, Caridi G, Rosano C, Pigullo S, et al. Severe congenital neutropenia: a negative synergistic effect of multiple mutations of ELANE (ELA2) gene. Br J Haematol 2009; 146:578–580. Lanciotti M, Indaco S, Bonanomi S, Coliva T, et al. Novel HAX1 gene mutations associated to neurodevelopment abnormalities in two Italian patients with severe congenital neutropenia. Haematologica 2010; 95:168–169. Lidar M, Kedem R, Berkun Y, Langevitz P, et al. Familial Mediterranean Fever in Ashkenazi Jews: The Mild End of the Clinical Spectrum. J Rheumatol 2010; 37:422–425. Lunden L, Boxhammer S, Carlsson G, Ellstrom KG, et al. Double de novo mutations of ELANE (ELA2) in a patient with severe congenital neutropenia requiring high-dose G-CSF therapy. Br J Haematol 2009; 147:587–590. Meng RH, Bridgman R, Toivio-Kinnucan M, Niemeyer GP, et al. Neutrophil elastase-processing defect in cyclic hematopoietic dogs. Exp Hematol 2010; 38:104–115. Notarangelo LD, Casanova JL. Primary immunodeficiencies: increasing market share. Curr Opin Immunol 2009; 21:461–465. Orstavik KH. X chromosome inactivation in clinical practice [Review]. Hum Genet 2009; 126:363–373. Osband AJ, Laskow DA, Berkowicz T, Mann RA. Fever and Neutropenia Following Simultaneous Pancreas-Kidney Transplantation. Am J Kidney Dis 2009; 54:XXXV– XXXVII. Qasim W, Gaspar HB, Thrasher AJ. Progress and prospects: gene therapy for inherited immunodeficiencies [Review]. Gene Ther 2009; 16:1285–1291. Renner ED, Hartl D, Rylaarsdam S, Young ML, et al. ComelNetherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 2009; 124:536–543.


Myeloid biology Inflammation and infection 69 Rezaei N, Moazzami K, Aghamohammadi A, Klein C. Neutropenia and Primary Immunodeficiency Diseases [Review]. Int Rev Immunol 2009; 28:335–366. Romero Z, Toscano MG, Unciti JD, Molina IJ, et al. Safer Vectors for Gene Therapy of Primary Immunodeficiencies [Review]. Curr Gene Ther 2009; 9:291–305. Shen YP, Dies KA, Holm IA, Bridgemohan C, et al. Clinical Genetic Testing for Patients With Autism Spectrum Disorders. Pediatrics 2010; 125:E727–E735. Skokowa J, Fobiwe JP, Dan L, Thakur BK, et al. Neutrophil elastase is severely down-regulated in severe congenital neutropenia independent of ELA2 or HAX1 mutations but dependent on LEF-1. Blood 2009; 114:3044–3051. Szabolcs P, Cavazzana-Calvo M, Fischer A, Veys P. Bone Marrow Transplantation for Primary Immunodeficiency Diseases. Pediatr Clin North Am 2010; 57:207–. Szczawinska-Poplonyk A, Gerreth K, Breborowicz A, Borysewicz-Lewicka M. Oral manifestations of primary immune deficiencies in children. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108:E9–E20. Videm V, Olsen GD. No relationship between neutrophil granulocyte activation and the myeloperoxidase gene129 G > A and-463 G > A promoter polymorphisms: implications for investigations of cardiovascular disease. Coron Artery Dis 2009; 20:446–452. Xia J, Bolyard AA, Rodger E, Stein S, et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol 2009; 147:535–542. Yesilipek MA, Tezcan G, Germeshausen M, Kupesiz A, et al. Unrelated cord blood transplantation in children with severe congenital neutropenia. Pediatric Transplantation 2009; 13:777–781.

Myeloid leukaemia Abu Tarif MA, Krishna G, Statkevich P. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin 2010; 26:397–405. Beel K, Van denberghe P. G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica 2009; 94:1449–1452. Bird JA, McClain KL, Rosenblatt HM, Abramson SL, et al. Hemophagocytic lymphohistiocytosis in a patient with xlinked lymphoproliferative disease. Allergy Asthma Proc 2009; 30:458–462. Lehrnbecher T, Ethier MC, Zaoutis T, Creutzig U, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol 2009; 147:125–128. Ma Y, Chen BB, Xu XP, Lin GW. Myeloid/natural killer cell precursor acute leukemia with multiple subcutaneous nodules as the initial presentation: a case report and literature review. Int J Hematol 2009; 90:243–247. Moller T, Nielsen OJ, Welinder P, Dunweber A, et al. Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia. Eur J Haematol 2010; 84:316–322. Rolston KVI. The Use of New and Better Antibiotics for Bacterial Infections in Patients With Leukemia. Clinical Lymphoma Myeloma 2009; 9:S357–S363. Sato M, Kako S, Oshima K, Sato K, et al. Prediction of infectious events by high-sensitivity C-reactive protein level before undergoing chemotherapy for acute myeloid leukaemia. Scand J Infect Dis 2010; 42:97–101. Schalk E, Bohr URM, Konig B, Scheinpflug K, et al. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol 2010; 89:9–14. Wimazal F, Germing U, Kundi M, Noesslinger T, et al. Evaluation of the Prognostic Significance of Eosinophilia and Basophilia in a Larger Cohort of Patients With Myelodysplastic Syndromes. Cancer 2010; 116:2372– 2381. Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, et al. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica 2010; 95:406–414. Yamada R, Horikawa K, Ishihara S, Hoshino K, et al. Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug. Int J Hematol 2010; 91:711–715. Zhou J, Zhang YM, Li JM, Li XX, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood 2010; 115:1697– 1702.

Inflammation and infection Aridon P, Ragonese P, Mazzola MA, Terruso V, et al. Leprosy: report of a case with severe peripheral neuropathy. Neurol Sci 2010; 31:75–77. Arlaud K, Gorincour G, Bouvenot J, Dutau H, et al. Could CT scan avoid unnecessary flexible bronchoscopy in children with active pulmonary tuberculosis? A retrospective study. Arch Dis Child 2010; 95:125–129. Azoulay E, Darmon M. Acute respiratory distress syndrome during neutropenia recovery - art. no. 114. Crit Care 2010; 14:114. Biwersi C, Hepping N, Bode U, Fleischhack G, et al. Bloodstream infections in a German paediatric oncology unit: Prolongation of inpatient treatment and additional costs. Int J Hyn Environ Health 2009; 212:541–546. Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA. Disseminated Fusarium Infection Originating From Paronychia in a Neutropenic Patient: A Case Report and Review of the Literature [Review]. Cutis 2010; 85:191– 194. Chu P, Sadullah S. The current role of amphotericin B lipid complex in managing systemic fungal infections. Curr Med Res Opin 2009; 25:3011–3020. Colucci G, Domenighetti G, Della Bruna R, Bonilla J, et al. Comparison of two non-bronchoscopic methods for evaluating inflammation in patients with acute hypoxaemic respiratory failure - art. no. R134. Crit Care 2009; 13:R134. Dehority W, Willert J, Pong A. Zygomycetes Infections in Pediatric Hematology Oncology Patients A Case Series and Review of the Literature. J Pediatr Hematol Oncol 2009; 31:911–919. Doi Y, Paterson DL, Egea P, Pascual A, et al. Extendedspectrum and CMY-type beta-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clin Microbiol Infect 2010; 16:33–38. Drake KW, Adam RD. Coccidioidal meningitis and brain abscesses Analysis of 71 cases at a referral center. Neurology 2009; 73:1780–1786. Dubberke ER, Reske KA, Srivastava A, Sadhu J, et al. Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2010; 24:192–198. Freeman AF, Olivier KN, Rubio TT, Bartlett G, et al. Intrathoracic Nontuberculous Mycobacterial Infections in Otherwise Healthy Children. Pediatr Pulmonol 2009; 44:1051– 1056. Fuxe J, Lashnits E, O’Brien S, Baluk P, et al. Angiopoietin/Tie2 Signaling Transforms Capillaries into Venules Primed for Leukocyte Trafficking in Airway Inflammation. Am J Pathol 2010; 176:2009–2018. Gill JS, Sandhu S, Gill S. Primary tuberculosis masquerading as gingival enlargement. Br Dent J 2010; 208:343–345. Gompelmann DR, Kappes J, Heussel CP, Herth FJF. Sarcoidosis, chronic obstructive pulmonary disease and viral hepatitis - a challenge for diagnostic and therapy [German]. Dtsch Med Wochenschr 2010; 135:184– 187. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, et al. Bacteraemia due to extended-spectrum beta-lactamaseproducing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010; 65:333–341. Halpern M, Balbi E, Carius L, Roma J, et al. Cellulitis and Nodular Skin Lesions Due to Fusarium spp in Liver Transplant: Case Report. Transplant Proc 2010; 42:599– 600. Han ES, Mekasha S, Ingalls RR. Fibroblast growth factorinducible 14 (Fn14) is expressed in the lower genital tract and may play a role in amplifying inflammation during infection. J Reprod Immunol 2010; 84:16–23. Hood JR, Burton D, Wilkinson JM, Cavanagh HMA. Antifungal activity of Leptospermum petersonii oil volatiles against Aspergillus spp. in vitro and in vivo. J Antimicrob Chemother 2010; 65:285–288. Jossi M, Ambrosioni J, Macedo-Vinas M, Garbino J. Invasive fusariosis with prolonged fungemia in a patient with acute lymphoblastic leukemia: case report and review of the literature. Int J Infect Dis 2010; 14:E354– E356. Kelly MJ, Vivier PM, Panken TM, Schwartz CL. Bacteremia in Febrile Nonneutropenic Pediatric Oncology Patients. Pediatric Blood Cancer 2010; 54:83–87. Kluger N, Cohen P, Fallet-Bianco C, Guillevin L. Mycobacterium chelonae infection under adalimumab therapy for spondylarthritis. Clin Exp Rheumatol 2010; 28:101–102.

Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, et al. Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 20012006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091–1100. Ladd AM, Goyal R, Rosainz L, Baiocco P, et al. Pulmonary embolism and portal vein thrombosis in an immunocompetent adolescent with acute cytomegalovirus hepatitis. J Thrombosis Thrombolysis 2009; 28:496–499. Lee HY, Schripsema JH, Sigar IM, Murray CM, et al. A link between neutrophils and chronic disease manifestations of Chlamydia muridarum urogenital infection of mice. FEMS Immunol Med Microbiol 2010; 59:108–116. Li JYZ, Yong TY, Coleman M, Astill D, et al. Bilateral renal inflammatory pseudotumour effectively treated with corticosteroid. Clin Exp Nephrol 2010; 14:190–198. Linden PK. Approach to the Immunocompromised Host with Infection in the Intensive Care Unit. Infect Dis Clin North Am 2009; 23:535–. Lunel FMV, Mennink-Kersten MASH, Ruegebrink D, van der Lee HAL, et al. Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagn Microbiol Infect Dis 2009; 64:408– 415. Manfredi R, Dentale N, Piergentili B, Pultrone C, et al. Tubercular Disease Caused by Bacillus of CalmetteGuerin as a Local Adjuvant Treatment of Relapsing Bladder Carcinoma. Cancer Biother Radiopharm 2009; 24:621–627. Mann PA, McNicholas PM, Chau AS, Patel R, et al. Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species. Antimicrob Agents Chemother 2009; 53:5026–5034. Maschmeyer G, Calandra T, Singh N, Wiley J, et al. Invasive mould infections: a multi-disciplinary update [Review]. Medical Mycology 2009; 47:571–583. Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: Practical consideration for clinicians [Review]. Gastroenterol Clin Biol 2009; 33:S158–S173. Meneses A, Epaulard O, Maurin M, Gressin R, et al. Brucella bacteremia reactivation 70 years after the primary infection [French]. Med Mal Infect 2010; 40:238– 240. Mikulska M, Raiola AM, Bruno B, Furfaro E, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44:361– 370. Morgan EA, Henrich TJ, Jarell AD, Shieh WJ, et al. Infectious Granulomatous Dermatitis Associated With Rothia mucilaginosa Bacteremia: A Case Report. Am J Dermatopathol 2010; 32:175–179. Moriyama B, Henning SA, Childs R, Holland SM, et al. HighDose Continuous Infusion beta-Lactam Antibiotics for the Treatment of Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients. Ann Pharmacother 2010; 44:929–935. Nathwani D. Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin [Review]. J Antimicrob Chemother 2009; 63:447–453. Nathwani D. Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin [Review]. J Antimicrob Chemother 2009; 64:447–453. Neel A, Pagnoux C. Primary angiitis of the central nervous system [Review]. Clin Exp Rheumatol 2009; 37:S95– S107. Pagano L, Caira M, Candoni A, Offidani M, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95:644–650. Pagano L, Valentini CG, Fianchi L, Caira M. The role of neutrophils in the development and outcome of zygomycosis in haematological patients. Clin Microbiol Infect 2009; 15:33–36. Pandey A, Kumar V, Gangopadhyay AN, Sharma SP, et al. Chronic bilious vomiting in children in developing countries due to high bowel obstruction: not always malrotation or tuberculosis. Pediatr Surg Int 2010; 26:213–217. Pizzo G, Lo Re D, Piscopo MR, Pizzo I, et al. Genetic disorders and periodontal health: A literature review [Review]. Med Sci Monitor 2009; 15:RA167–RA178. Pradeep TG, Prabhakaran VC, Mcnab A, Dodd T, et al. Diffuse Bilateral Orbital Inflammation in Churg-Strauss Syndrome. Ophthal Plast Reconstr Surg 2010; 26:57–59.


70 Myeloid biology Miscellaneous Quilty S, Kwok G, Hajkowicz K, Currie B. High incidence of methicillin-resistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital. Internal Med J 2009; 39:557–559. Quintas-Cardama A, Santos FPD, Kantarjian H, O’Brien S, et al. Dynamics and Management of Cytopenias Associated With Dasatinib Therapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Imatinib Failure. Cancer 2009; 115:3935–3943. Rangaraj G, Granwehr BP, Jiang Y, Hachem R, et al. Perils of Quinolone Exposure in Cancer Patients Breakthrough Bacteremia With Multidrug-Resistant Organisms. Cancer 2010; 116:967–973. Sikkeland LIB, Eduard W, Stangeland AM, Thorgersen EB, et al. Occupational exposure to bacterial single cell protein induces inflammation in lung and blood. Inhalat Toxicol 2009; 21:674–681. Soontrapa P, Larbcharoensub N, Luxameechanporn T, Cheewaruangroj W, et al. Fungal rhinosinusitis: a retrospective analysis of clinicopathologic features and treatment outcomes at ramathibodi hospital. Southeast Asian J Trop Med Public Health 2010; 41:442–449. Suzuki K, Nakase K, Kyo T, Kohara T, et al. Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur J Haematol 2010; 84:441–447. Tewari S, Sharma RK, Abrol P, Sen R. Necrotizing stomatitis: a possible periodontal manifestation of deferiproneinduced agranulocytosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108:E13–E19. Thorgersen EB, Hellerud BC, Nielsen EW, Barratt-Due A, et al. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J 2010; 24:712–722. Wingard J. Antifungal Management. Biol Blood Marrow Transplant 2010; 16:441–442. Yu OHY, Keet AWW, Sheppard DC, Brewer T. Articular aspergillosis: case report and review of the literature [Review]. Int J Infect Dis 2010; 14:E433–E435. Zaki MES, Ashray RE. Clinical and hematological study for Parvovirus b19 infection in children with acute leukemia. Int J Lab Hematol 2010; 32:159–166. Zeitz J, Huber M, Rogler G. Serious Course of a Miliary Tuberculosis in a 34-Year-Old Patient with Ulcerative Colitis and HIV Infection under Concomitant Therapy with Infliximab [German]. Med Klin 2010; 105:314–318. Zhang Y, Zhang MN, Jiang CH, Yao Y. Development of sympathetic ophthalmia following globe injury. Chin Med J 2009; 122:2961–2966. Zoli A, Massi G, Pinnelli M, Lo Cuccio CD, et al. Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept. Clin Rheumatol 2010; 29:99– 101.

Miscellaneous Bajwa EK, Khan UA, Januzzi JL, Gong MN, et al. Plasma CReactive Protein Levels Are Associated With Improved Outcome in ARDS. Chest 2009; 136:471–480. Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, et al. Immunodeficiencies. Clin Exp Immunol 2009; 158:14–22. Beckman JD, Belcher JD, Vineyard JV, Chen CS, et al. Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. Am J Physiol-Heart Circul Physiol 2009; 297:H1243–H1253.

Boztug K, Hauck FH, Wintergerst U, Klein C. Quantitative and qualitative defects of neutrophilic granulocytes [Review] [German]. Monatsschr Kinderheilkd 2009; 157:861. Carroll TL, Gartner-Schmidt J, Statham MM, Rosen CA. Vocal Process Granuloma and Glottal Insufficiency: An Overlooked Etiology? Laryngoscope 2010; 120:114– 120. Chinen J, Shearer WT. Advances in basic and clinical immunology in 2009. J Allergy Clin Immunol 2010; 125:563–568. Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, et al. Spinal Cord Sarcoidosis Clinical and Laboratory Profile and Outcome of 31 Patients in a Case-Control Study. Medicine 2010; 89:133–140. Gaillard-Le Roux B, Mechinaud F, Gay-Andrieu F, Lortholary O, et al. Successful Triple Combination Therapy of Disseminated Absidia corymbifera Infection in an Adolescent With Osteosarcoma. J Pediatr Hematol Oncol 2010; 32:131–133. Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, et al. "Short Course" Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma. Biol Blood Marrow Transplant 2010; 16:70–77. Ghadimi D, de Vrese M, Heller KJ, Schrezenmeir J. Effect of Natural Commensal-Origin DNA on Toll-like Receptor 9 (TLR9) Signaling Cascade, Chemokine IL-8 Expression, and Barrier Integritiy of Polarized Intestinal Epithelial Cells. Inflamm Bowel Dis 2010; 16:410–427. Haglund C, Aleskog A, Hakansson LD, Hoglund M, et al. The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing. Toxicol Lett 2010; 194:102–107. Hayakawa T, Jin CX, Ko SBH, Kitagawa M, et al. Lactoferrin in Gastrointestinal Disease [Review]. Intern Med 2009; 48:1251–1254. Jamoussi SK, Maamouri N, Ben Dhaou B, Baili L, et al. Liver involvement in sarcoidosis: Study of seven cases [French]. Rev Med Interne 2010; 31:12–16. Joshi SS, Romanelli P, Kirsner RS. Sarcoidosis Mimicking a Venous Ulcer: A Case Report. Ostomy Wound Manag 2009; 55:46–48. Kim YK, Sohn SK, Lee JH, Yang DH, et al. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 2010; 89:475–482. Koufane J, Afifi Y, Khoudri I, Rmili M, et al. Baker Rosenbach erysipeloid appearing as a granulomatous cheilitis [French]. Ann Dermatol Venereol 2010; 137:124–127. Lee KS, Na DH. Capillary Electrophoretic Separation of Poly(ethylene glycol)-Modified Granulocyte-Colony Stimulating Factor. Arch Pharm Res 2010; 33:491– 495. Logters T, Margraf S, Altrichter J, Cinatl J, et al. The clinical value of neutrophil extracellular traps [Review]. Med Microbiol Immunol (Berl) 2009; 198:211–219. Mahieu LM, Van Gasse N, Wildemeersch D, Jansens H, et al. Number of sites of perinatal Candida colonization and neutropenia are associated with nosocomial candidemia in the neonatal intensive care unit patient. In: Pediatric Critical Care Med 2010; 11:240–245.

Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E, Beneton N, et al. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro. Eur J Dermatol 2010; 20:68–73. Maschmeyer G, Neuburger S, Fritz L, Bohme A, et al. A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol 2009; 20:1560–1564. Meis S, Hamacher A, Hongwiset D, Marzian C, et al. NF546 [4,4 ’-(Carbonylbis(imino-3,1-phenylene-carbonylimino3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylenealpha,alpha ’-diphosphonic Acid) Tetrasodium Salt] Is a Non-Nucleotide P2Y(11) Agonist and Stimulates Release of Interleukin-8 from Human Monocyte-Derived Dendritic Cells. J Pharmacol Exp Ther 2010; 332:238–247. Nunes H, Uzunhan Y, Freynet O, Naccache JM, et al. Thoracic sarcoidosis [French]. Presse Med 2010; 39:93–106. Oak NR, Triulzi DJ. Granulocyte Transfusion Therapy in Abdominal Organ Transplant Recipients. J Clin Apheresis 2009; 24:186–189. Ocal K, Dag A, Turkmenoglu O, Kara T, et al. Granulomatous Mastitis: Clinical, Pathological Features, and Management. Breast J 2010; 16:176–182. Park JW, Chung JW. Long-term treatment of Langerhans cell histiocytosis of the mandibular condyle with indomethacin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:E13–E21. Pedroso VSP, Vilela MD, Pedroso ERP, Teixeira AL. Paracoccidioidomycosis compromising the central nervous system: a systematic review of the literature [Review] [Portuguese]. Revista da Sociedade Brasileira de Medicina Tropical 2009; 42:691–697. Pessina A, Bonomi A, Baglio C, Cavicchini L, et al. Refinement and Optimisation of the Rat CFU-GM Assay to Incorporate the Use of Cryopreserved Bone-marrow Cells for In Vitro Toxicology Applications. ATLA-Altern Lab Anim 2009; 37:417–425. Riera NE, Salto MR, Canalejo K, Felippo ME, et al. Neutrophils without CD16(b) receptors. [Spanish]. Med-Buenos Aires 2009; 69:442–446. Ruokonen H, Helve T, Arola J, Hietanen J, et al. "Strawberry like" gingivitis being the first sign of Wegener’s granulomatosis. Eur J Intern Med 2009; 20:651–653. Sahlander K, Larsson K, Palmberg L. Altered innate immune response in farmers and smokers. Innate Immun 2010; 16:27–38. Semeraro M, Thomee C, Rolland E, Le Deley MC, et al. A Predictor of Unfavourable Outcome in Neutropenic Paediatric Patients Presenting With Fever of Unknown Origin. Pediatric Blood Cancer 2010; 54:284–290. Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent Primary Biliary Cirrhosis After Liver Transplantation [Review]. Am J Transplant 2010; 10:720–726. Steinfort DP, Smallwood D, Antippa P, Irving LB. Endobronchial extension of granulomatous lymphadenitis in an HIV-positive man with immune reconstitution syndrome. Respirology 2009; 14:1064–1066. Tremezaygues L, Schmaltz R, Vogt T, Reichrath J. Management of pyoderma gangrenosum - An update on clinical features, diagnosis and therapy [German]. Hautarzt 2010; 61:345–353. van Hasselt W, Schreuder RM, Houwerzijl EJ. Periorbital oedema. Neth J Med 2009; 67:338–339.


Current world literature. Infection.

Current world literature: current opinion in pediatrics.

Current world literature. Renal immunology and pathology.

Bibliography of the current world literature in hypertension.

Bibliography of the current world literature in hypertension.

Bibliography of the current world literature in hypertension.

Bibliography of the current world literature in hypertension.

Bibliography of the current world literature in hypertension.

Bibliography of the current world literature in hypertension.

Bibliography of the current world literature in hypertension.

From a word to a world: the current situation in the interdisciplinary field of synthetic biology.

A new world for Open Biology.

Current Protocols in Mouse Biology.

Current Challenges in Bone Biology.

Current Medical Literature.

Current Medical Literature.

Current Medical Literature.

Current Medical Literature.

Current Medical Literature.

Current Medical Literature.

Current Medical Literature.

Current Medical Literature.

Current concepts of reproductive immuno-biology.

Citations from world literature. Nutrition; metabolism.